Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Satralizumab - Chugai Pharmaceuticals/Roche

Next Previous
X
Search
Drug Profile

Satralizumab - Chugai Pharmaceuticals/Roche

Alternative Names: ENSPRYNG; RG-6168; SA-237; Satralizumab-mwge

Latest Information Update: 13 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Roche
  • Class Anti-inflammatories; Antirheumatics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuromyelitis optica
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neuromyelitis optica
  • Phase III Encephalitis; Graves ophthalmopathy
  • No development reported Rheumatoid arthritis
  • Discontinued Myasthenia gravis

Most Recent Events

  • 10 Jun 2024 Hoffmann-La Roche plans to initiate a phase II (SHIELD DMD) trial for Duchenne Muscular Dystrophy (In children, In Adolescents) in the US (SC) (NCT06450639)
  • 28 May 2024 Hoffmann-La Roche completes the phase III SAkuraMoon trial in Neuromyelitis optica (Montherpay, Combination therapy, In adolescents, In the elderly, In adults) in USA, Ukraine, Turkey, Taiwan, Spain, South Korea, Romania, Puerto Rico, Malaysia, Japan, Croatia, Canada, Italy (SC, Injection) (NCT04660539) (EudraCT2020-003413-35)
  • 09 May 2024 Discontinued - Phase-III for Myasthenia gravis (In adolescents, In the elderly, In adults) in Argentina, Australia, Brazil, China, Canada, France, Germany, Italy, Japan, South Korea, Poland, Russia, Spain, Turkey, Taiwan, USA, Netherlands, Denmark (SC) (Roche pipeline, May 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top